The improved antitumor efficacy of continuous intratumoral chemotherapy with cisplatin-loaded implants for the treatment of sarcoma 180 tumor-bearing mice
Cisplatin is the most commonly used antitumor drug in the chemotherapy of a variety of malignancies. However, the severe side effects and drug resistance limit its clinical application. The aim of this study was to develop PLGA-based cisplatin-loaded implants and evaluate the antitumor efficacy of c...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-01-01
|
| Series: | Drug Delivery |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/10717544.2019.1574938 |
| _version_ | 1819070027933941760 |
|---|---|
| author | Li Gao Shang Cai Awei Cai Yang Zhao Tangbing Xu Yan Ma Yan Xu Yuan Wang Hao Wang Yong Hu |
| author_facet | Li Gao Shang Cai Awei Cai Yang Zhao Tangbing Xu Yan Ma Yan Xu Yuan Wang Hao Wang Yong Hu |
| author_sort | Li Gao |
| collection | DOAJ |
| description | Cisplatin is the most commonly used antitumor drug in the chemotherapy of a variety of malignancies. However, the severe side effects and drug resistance limit its clinical application. The aim of this study was to develop PLGA-based cisplatin-loaded implants and evaluate the antitumor efficacy of continuous intratumoral chemotherapy with the implants. The cisplatin-loaded implants were prepared by the direct compression method and characterized regarding drug content, micromorphology, in vitro and in vivo drug release profiles. Furthermore, the antitumor activity of the implants was conducted in sarcoma 180 tumor-bearing mice. The SEM images showed smooth surface of the implants and the mean drug content of the tested implants was (37.7% ± 0.5%, w/w). Both in vitro and in vivo release profiles of the implants were characterized by initial burst release followed by the sustained-release of cisplatin. Intratumoral implantation of the cisplatin-loaded implants could effectively inhibit the tumor growth. Additionally, intratumoral chemotherapy with the implants significantly reduced the systemic toxicity compared with intravenous injection of cisplatin. It is worth noting that an increase in the dose of the implants led to a higher tumor suppression rate without additional systemic toxicity. These results demonstrated that cisplatin-loaded implants enhanced the antitumor efficacy and reduced the dose-related side effects in sarcoma 180 tumor-bearing mice. |
| first_indexed | 2024-12-21T16:59:25Z |
| format | Article |
| id | doaj.art-78d39dc71d184cc29413b3e6365d0271 |
| institution | Directory Open Access Journal |
| issn | 1071-7544 1521-0464 |
| language | English |
| last_indexed | 2024-12-21T16:59:25Z |
| publishDate | 2019-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Drug Delivery |
| spelling | doaj.art-78d39dc71d184cc29413b3e6365d02712022-12-21T18:56:41ZengTaylor & Francis GroupDrug Delivery1071-75441521-04642019-01-0126120821510.1080/10717544.2019.15749381574938The improved antitumor efficacy of continuous intratumoral chemotherapy with cisplatin-loaded implants for the treatment of sarcoma 180 tumor-bearing miceLi Gao0Shang Cai1Awei Cai2Yang Zhao3Tangbing Xu4Yan Ma5Yan Xu6Yuan Wang7Hao Wang8Yong Hu9Hefei University of TechnologyFirst Affiliated Hospital of Anhui Medical UniversityFirst Affiliated Hospital of Anhui Medical UniversityThe Second People’s Hospital of HefeiFourth Affiliated Hospital of Anhui Medical UniversityHefei University of TechnologyHefei University of TechnologyFirst Affiliated Hospital of Anhui Medical UniversityFirst Affiliated Hospital of Anhui Medical UniversityFirst Affiliated Hospital of Anhui Medical UniversityCisplatin is the most commonly used antitumor drug in the chemotherapy of a variety of malignancies. However, the severe side effects and drug resistance limit its clinical application. The aim of this study was to develop PLGA-based cisplatin-loaded implants and evaluate the antitumor efficacy of continuous intratumoral chemotherapy with the implants. The cisplatin-loaded implants were prepared by the direct compression method and characterized regarding drug content, micromorphology, in vitro and in vivo drug release profiles. Furthermore, the antitumor activity of the implants was conducted in sarcoma 180 tumor-bearing mice. The SEM images showed smooth surface of the implants and the mean drug content of the tested implants was (37.7% ± 0.5%, w/w). Both in vitro and in vivo release profiles of the implants were characterized by initial burst release followed by the sustained-release of cisplatin. Intratumoral implantation of the cisplatin-loaded implants could effectively inhibit the tumor growth. Additionally, intratumoral chemotherapy with the implants significantly reduced the systemic toxicity compared with intravenous injection of cisplatin. It is worth noting that an increase in the dose of the implants led to a higher tumor suppression rate without additional systemic toxicity. These results demonstrated that cisplatin-loaded implants enhanced the antitumor efficacy and reduced the dose-related side effects in sarcoma 180 tumor-bearing mice.http://dx.doi.org/10.1080/10717544.2019.1574938cisplatinimplantssustained releaseplgaintratumoral chemotherapy |
| spellingShingle | Li Gao Shang Cai Awei Cai Yang Zhao Tangbing Xu Yan Ma Yan Xu Yuan Wang Hao Wang Yong Hu The improved antitumor efficacy of continuous intratumoral chemotherapy with cisplatin-loaded implants for the treatment of sarcoma 180 tumor-bearing mice Drug Delivery cisplatin implants sustained release plga intratumoral chemotherapy |
| title | The improved antitumor efficacy of continuous intratumoral chemotherapy with cisplatin-loaded implants for the treatment of sarcoma 180 tumor-bearing mice |
| title_full | The improved antitumor efficacy of continuous intratumoral chemotherapy with cisplatin-loaded implants for the treatment of sarcoma 180 tumor-bearing mice |
| title_fullStr | The improved antitumor efficacy of continuous intratumoral chemotherapy with cisplatin-loaded implants for the treatment of sarcoma 180 tumor-bearing mice |
| title_full_unstemmed | The improved antitumor efficacy of continuous intratumoral chemotherapy with cisplatin-loaded implants for the treatment of sarcoma 180 tumor-bearing mice |
| title_short | The improved antitumor efficacy of continuous intratumoral chemotherapy with cisplatin-loaded implants for the treatment of sarcoma 180 tumor-bearing mice |
| title_sort | improved antitumor efficacy of continuous intratumoral chemotherapy with cisplatin loaded implants for the treatment of sarcoma 180 tumor bearing mice |
| topic | cisplatin implants sustained release plga intratumoral chemotherapy |
| url | http://dx.doi.org/10.1080/10717544.2019.1574938 |
| work_keys_str_mv | AT ligao theimprovedantitumorefficacyofcontinuousintratumoralchemotherapywithcisplatinloadedimplantsforthetreatmentofsarcoma180tumorbearingmice AT shangcai theimprovedantitumorefficacyofcontinuousintratumoralchemotherapywithcisplatinloadedimplantsforthetreatmentofsarcoma180tumorbearingmice AT aweicai theimprovedantitumorefficacyofcontinuousintratumoralchemotherapywithcisplatinloadedimplantsforthetreatmentofsarcoma180tumorbearingmice AT yangzhao theimprovedantitumorefficacyofcontinuousintratumoralchemotherapywithcisplatinloadedimplantsforthetreatmentofsarcoma180tumorbearingmice AT tangbingxu theimprovedantitumorefficacyofcontinuousintratumoralchemotherapywithcisplatinloadedimplantsforthetreatmentofsarcoma180tumorbearingmice AT yanma theimprovedantitumorefficacyofcontinuousintratumoralchemotherapywithcisplatinloadedimplantsforthetreatmentofsarcoma180tumorbearingmice AT yanxu theimprovedantitumorefficacyofcontinuousintratumoralchemotherapywithcisplatinloadedimplantsforthetreatmentofsarcoma180tumorbearingmice AT yuanwang theimprovedantitumorefficacyofcontinuousintratumoralchemotherapywithcisplatinloadedimplantsforthetreatmentofsarcoma180tumorbearingmice AT haowang theimprovedantitumorefficacyofcontinuousintratumoralchemotherapywithcisplatinloadedimplantsforthetreatmentofsarcoma180tumorbearingmice AT yonghu theimprovedantitumorefficacyofcontinuousintratumoralchemotherapywithcisplatinloadedimplantsforthetreatmentofsarcoma180tumorbearingmice AT ligao improvedantitumorefficacyofcontinuousintratumoralchemotherapywithcisplatinloadedimplantsforthetreatmentofsarcoma180tumorbearingmice AT shangcai improvedantitumorefficacyofcontinuousintratumoralchemotherapywithcisplatinloadedimplantsforthetreatmentofsarcoma180tumorbearingmice AT aweicai improvedantitumorefficacyofcontinuousintratumoralchemotherapywithcisplatinloadedimplantsforthetreatmentofsarcoma180tumorbearingmice AT yangzhao improvedantitumorefficacyofcontinuousintratumoralchemotherapywithcisplatinloadedimplantsforthetreatmentofsarcoma180tumorbearingmice AT tangbingxu improvedantitumorefficacyofcontinuousintratumoralchemotherapywithcisplatinloadedimplantsforthetreatmentofsarcoma180tumorbearingmice AT yanma improvedantitumorefficacyofcontinuousintratumoralchemotherapywithcisplatinloadedimplantsforthetreatmentofsarcoma180tumorbearingmice AT yanxu improvedantitumorefficacyofcontinuousintratumoralchemotherapywithcisplatinloadedimplantsforthetreatmentofsarcoma180tumorbearingmice AT yuanwang improvedantitumorefficacyofcontinuousintratumoralchemotherapywithcisplatinloadedimplantsforthetreatmentofsarcoma180tumorbearingmice AT haowang improvedantitumorefficacyofcontinuousintratumoralchemotherapywithcisplatinloadedimplantsforthetreatmentofsarcoma180tumorbearingmice AT yonghu improvedantitumorefficacyofcontinuousintratumoralchemotherapywithcisplatinloadedimplantsforthetreatmentofsarcoma180tumorbearingmice |